The Expanding Role of Immune Globulin Treatment in Diseases: Utilization and Growth

Immune globulin therapy has expanded well beyond its original use in primary immune deficiency. New research, improved diagnostics and growing recognition of autoimmune neurological conditions are driving both utilization and market growth. Here is what the latest data and clinical perspectives reveal.

At a Glance

-IG therapy treats primary immune deficiency, secondary immune deficiency and a growing range of neurological and autoimmune conditions

– U.S. IVIG and SCIG administrations per 100,000 person-years rose 120 percent (commercial) and 144 percent (Medicare) from 2009 to 2019

– Average annual IG demand has grown more than 7 percent per year over the last five years, a trend extending back to the mid-1980s

– Two new 10 percent IVIG products — Yimmugo (Grifols/Biotest) and ALYGLO (GC Biopharma) — received FDA marketing approval in the past year

– Access challenges remain: limited FDA-approved indications, high per-patient costs, and supply tension between adult neurological dosing and pediatric replacement therapy

Sales of immune globulin (IG) are up. According to the Marketing Research Bureau (MRB), manufacturer-level sales of intravenous IG (IVIG) in grams grew more than 10 percent in 2023 compared to 2022.¹ Matthew Hotchko, president of MRB, explained that the various disruptions related to the COVID-19 pandemic caused IG demand to drop in 2021 and recover in 2022 and 2023. “The particularly high 10 percent-plus growth rate in IG demand that we saw in 2023 may partly reflect a catch-up effect, as undiagnosed patients whose access to specialist care was delayed by the pandemic finally received their diagnoses and prescriptions for IG therapy,” he says.

Hogan Lovells, a global law firm specializing in commercial, regulatory and legal issues, conducted a roundtable discussion focused on access to and use of IG therapies and published its conclusions in the Hogan Lovells Roundtable Report in May 2022. The report found that each year in the United States, approximately 275,000 patients are treated with IVIG and subcutaneous IG (SCIG) therapies for a variety of conditions. “In 2020, roughly 110 million grams of IG were used to treat patients,” according to the report. “These patients have conditions in more than eight medical specialties and receive treatment for hundreds of indications.”² Categories of conditions treated with IG therapy include primary immune deficiency (PI) — 30 percent or about 400 conditions; secondary immune deficiency (SID) — 17.5 percent or about 200 conditions; neurology — 40 percent or about 50 conditions; and all others — 12.5 percent or about 300 conditions.²

IG therapy is a medicine made from human blood plasma. The plasma is processed from donated human blood and contains antibodies that protect the body against diseases. Recently, the role of IG has expanded both in its utilization and growth, meaning more patients can benefit from IG therapy, which is often the only treatment for many rare, life-threatening chronic diseases and genetic conditions. IG therapy increases the chances of regular access to plasma medicines, which contributes to the improvement of health outcomes for patients.

Overview of the Expanding Role of Immune Globulin

– U.S. IVIG manufacturer-level sales grew more than 10 percent in 2023 vs. 2022, partly due to post-pandemic catch-up demand following disrupted specialist access during COVID-19

– Approximately 275,000 U.S. patients are treated annually with IVIG and SCIG across hundreds of indications in more than eight medical specialties

– Conditions treated include neurological disorders (40 percent), primary immune deficiency (30 percent), secondary immune deficiency (17.5 percent), and other conditions (12.5 percent)

– IG therapy is derived from donated human plasma and contains concentrated antibodies; for many rare, life-threatening diseases, it is the only available treatment

Indications

According to Terry Harville, MD, PhD, a professor of pathology and laboratory services and internal medicine at the University of Arkansas for Medical Sciences, IG therapy can be used as either 1) replacement therapy for people who are deficient in immunoglobulin (antibodies) or 2) immune modulation. “The initial intended use of IG therapy was for patients with antibody deficiencies to replace [the antibodies] they were missing,” he explained. “The earliest documented use was in patients with X-linked agammaglobulinemia, a [PI] affecting males who are unable to produce B lymphocytes and are thereby unable to make antibodies. Yet, this is considered a rare disorder, perhaps one in 1,000,000 live births. More commonly, IG replacement is used for patients diagnosed with CVID [common variable immune deficiency], of which some registries may have as many as one in 3,000 people, although most textbooks suggest one in 10,000 to 50,000 people.

“As with many new medications, for example, when cortisol became available, it was tried in many conditions which did not have better treatment options. One of the earliest was Kawasaki disease, where a total dose of two grams per kilogram of body weight infused over two to five days demonstrated benefit. From there, similar dosing has been used to treat thrombocytopenia and other hematologic cytopenias. Subsequently, it was tried for Guillain-Barré syndrome, where it was found to be as efficacious as undergoing plasmapheresis. Subsequently still, a variety of neurologic disorders, which for the most part can be considered some form of autoimmune encephalopathy, have had beneficial results. Related conditions such as PANDAS/PANS have benefit. We recently reported the use in patients with catatonia, which may be one of the rarest usages.”

Indications Overview:

– IG therapy serves two clinical purposes: replacing absent or insufficient immunoglobulin in patients with immune deficiency, and modulating the immune response in autoimmune conditions

– Common conditions treated include CVID (common variable immune deficiency), X-linked agammaglobulinemia (XLA), Kawasaki disease, thrombocytopenia, Guillain-Barré syndrome and a growing range of autoimmune encephalopathies

– Approximately 65 percent of U.S. IG prescriptions are for FDA-approved (on-label) indications; the remaining 35 percent is off-label but supported by treatment guidelines and real-world evidence

– Emerging uses include conditions such as PANDAS/PANS and catatonia, representing some of the newest frontiers in IG research

Utilization

The Hogan Lovells Roundtable Report showed that approximately 65 percent of IG use in the United States is on-label use, meaning it is prescribed to treat conditions for which the U.S. Food and Drug Administration (FDA) has granted approval. The other 35 percent is prescribed for off-label use to treat conditions for which it is medically acceptable according to existing treatment guidelines and evidence-based, real-world use.²

A study that described U.S. IG utilization patterns from 2009 to 2019 showed growth in both commercial and Medicare populations. Respectively, IG administrations per 100,000 person-years increased by 120 percent and 144 percent; IG recipients per 100,000 enrollees grew by 71 percent and 102 percent; average annual administrations per recipient rose by 28 percent and 19 percent; and average annual dose (grams) per recipient increased by 29 percent and 34 percent.³ The study also showed that IG administrations associated with immune deficiency per 100,000 person-years increased by 154 percent and 176 percent. Autoimmune and neurologic conditions were associated with higher annual average administrations and doses than other conditions.³

In contrast to the Hogan Lovells Roundtable Report, there is a consistent increase of non-specific IG use in Québec, Canada, according to Héma-Québec, a nonprofit organization that supplies blood and other human biological products to local hospitals. Québec’s Ministry of Health’s data for the use of IG reports that more than two million grams were administered at an average of 349.6 grams per user, or 232.⁴ grams per 1,000 people. The rate of Quebecers who have received IG is 67 recipients per 100,000 people. Nearly half of the IG used was administered for a neurological indication; nearly a third was administered for an immunological indication; and just under 10 percent was administered for hematological indications. PI was the medical condition for which IG was administered to the largest number of users (20.1 percent); chronic inflammatory demyelinating polyneuropathy (CIDP) was the medical condition for which the highest amount of IG was administered (21.6 percent or an average of 671.1 grams per patient); and in nearly 20 percent of users, IG was either administered for an unclear indication at 14.3 percent or absent at 4.7 percent. In total, this represents 15 percent of the quantities of IG.⁴

Keith Berman, MPH, MBA, founder of Health Research Associates and plasma industry consultant, says there are currently 12 unique licensed IVIG products, three of which are approved for SC administration. Three of the 12 IVIG products are available in both 5 percent and 10 percent IgG concentrations. There are also five unique licensed SCIG products, including HYQVIA, which is co-administered with a special agent that facilitates SC delivery of substantially increased doses of IG into the infusion site, thereby reducing infusion frequency.

Over the last year, two new 10 percent IVIG products have received FDA marketing approval — Yimmugo and ALYGLO. Manufactured by Grifols’ Biotest subsidiary, Yimmugo is expected to be available through Kedrion Biopharma in the first quarter of 2025. The Korean plasma products manufacturer GC Biopharma initiated its first shipments of ALYGLO in July 2024.

“Like other licensed IG preparations, these new IVIG products will likely be used as well for a wide range of off-label uses, including treatment of SIDs, as well as numerous immune-mediated hematological, neurological, neuromuscular, rheumatologic and other disorders,” says Berman.

Berman also notes that government health authorities in other countries — notably Australia and the United Kingdom — have published guidance for the clinical use of IG products based on the robustness of the evidence for effectiveness and safety. “The Australian national guidance indicates that IG has an established therapeutic role for the treatment of immune thrombocytopenic purpura in adults. In the example of bullous pemphigoid, IG has an emerging therapeutic role, indicating that there’s already some available evidence of benefit. But for other disorders, such as relapsing-remitting multiple sclerosis (RRMS), the guidance says IG use should be reserved for exceptional circumstances only,” said Berman.

Utilization Overview:

– U.S. IG administrations for immune deficiency conditions rose 154 percent (commercial) and 176 percent (Medicare) from 2009 to 2019, outpacing overall utilization growth

– In Québec, CIDP represented the highest-volume IG use at an average of 671.1 grams per patient, more than any other single condition

– There are currently 12 licensed IVIG products and two licensed SCIG products in the U.S., including HYQVIA, which uses a co-administration agent to enable higher-volume subcutaneous delivery

– Yimmugo (Grifols/Biotest, distributed by Kedrion Biopharma) and ALYGLO (GC Biopharma, first shipments July 2024) are the two most recently FDA-approved 10% IVIG products

Growth

Dr. Harville says the growth of IG treatment for different disease states can be attributed to solving the challenge of not suppressing the immune system: “An ideal IG therapy would provide only benefit and create no harm. With autoimmune disorders, the typical approach is to suppress the immune system. Therefore, the patient becomes susceptible to infections and can even be at risk for developing malignancies. Immune modulation via infusion of IG does not suppress immunity, taking away these risks. Furthermore, providing a large antibody experience from the donors can enhance the immune protection of the patient. Therefore, we can achieve benefit with low risk for harm to the patient.”

Dr. Harville also says the types of disease states that are seeing the most growth in IG treatment use include neurological disorders: “Initially used for demyelinating conditions with benefit, IG is now used for other autoimmune encephalopathies. As we obtain more information and gain a better understanding, we have found a large variety of autoimmune antibodies in the central nervous system. Therefore, modulation of these autoimmune antibodies can and do provide benefit to patients with neurological disorders.”

The most growth seen in IG treatment, he says, is in the subcutaneous infusion of replacement IG because it can reduce infusion-related side effects: “High-dose IG treatment is impractical subcutaneously because too much volume needs to be infused. Although, for some neurologic conditions such as CIDP, lower dosing and subcutaneous infusions work. Similarly, treatment of pemphigus may need doses less than used for IG replacement and may be amenable for SCIG infusion. Anti-phospholipid disease may also require lower dosing amenable for SCIG infusion.

Continued studies are needed to determine which disorders require the high pulse serum level of IG for efficacy, which could only be provided by intravenous infusion, versus those whereby other mechanisms of IG are helpful, such as the presence of anti-cytokine antibodies or anti-idiotypic antibodies, which are modulating immune function. In the latter, perhaps the slower introduction of IG via SC infusion may actually be of more benefit. Which poses the question: Is this why SCIG works well for CIDP treatment?”

Berman added that, both in the United States and abroad, growth in utilization of IG continues to be driven by the publication of new research documenting its therapeutic benefit in an ever-widening range of autoimmune, and in the case of transplantation alloimmune, disease states, as well as by growing numbers of patients diagnosed with secondary humoral immunodeficiency resulting from the growing use of B cell-depleting drugs that induce hypogammaglobulinemia (low IgG level).

“Over the last five years, the average annual growth rate in IG demand has exceeded seven percent, continuing nearly uninterrupted year-over-year growth that extends all the way back to the mid-1980s,” Berman explained. “The explanation for this remarkable growth begins with the fact that IG is the purified concentrate of many thousands of immunoregulatory and anti-infectious IgG antibodies, which makes it a vastly different kind of product than any drug or single-molecule biotherapeutic agent.”

Growth Overview:

– Unlike immunosuppressive therapies, IG immune modulation does not suppress the immune system, reducing infection risk and preserving immune protection — a key clinical advantage driving expanded use

– Neurological disorders, particularly autoimmune encephalopathies and conditions where autoimmune antibodies have been identified in the central nervous system, represent the fastest-growing area of IG use

– SCIG is growing in adoption for conditions responsive to lower, slower dosing — including CIDP, pemphigus, and anti-phospholipid disease — due to reduced infusion-related side effects and improved patient convenience

– Growth in secondary humoral immunodeficiency, resulting from increasing use of B cell-depleting drugs in oncology and rheumatology, is a significant and expanding driver of IG demand

Challenges to Utilization and Growth

According to Dr. Harville, broad use of IG therapy still has not been achieved because it has only a small number of FDA-approved indications, and IG therapy is expensive.

“When an autoimmune process is present, which could have theoretic benefit from IG infusion, it would be nice for third-party payers to allow a test usage. However, this raises a conflict if an infant with XLA may need five grams of IVIG a month whereas an adult with a neurological disease may need 200 grams of IVIG infusion several times,” Dr. Harville explained. “Therefore, one adult treatment could use an amount of IG which could treat 16 infants with XLA for a year. While all patients deserve the best treatment available, the high amounts used in adults with neurological diseases could result in less availability for ongoing treatment of patients with PI, especially if a manufacturing shortage was to occur.”

Challenges Overview:

– Limited FDA-approved indications and high treatment costs remain the two primary barriers to broader IG therapy access

– Dosing disparity creates supply tension: a single adult neurological treatment course may require as much IG as treating 16 infants with XLA for an entire year

– Inconsistent third-party payer coverage for off-label use limits access for patients who could benefit from IG therapy for conditions lacking FDA-approved labeling

– Manufacturing shortages, if they occur, disproportionately risk supply for patients with PI who depend on ongoing replacement therapy

Advances Contributing to the Growing Need of IG Treatment

Representing more than 1,000 human plasma collection centers in North America and Europe, as well as the manufacturers of plasma protein therapies, the Plasma Protein Therapeutics Association (PPTA) says its members produce approximately 80 percent of the plasma protein therapies in the United States and 60 percent of those manufactured in Europe.

The PPTA’s “Statement on Immunoglobulin Use to Meet Clinical Need” reports several advances are contributing to the growing clinical need of IG therapy: “Advances in the diagnosis, treatment and identification of many diseases has led to an increase in the number of patients treated with IG and other plasma-derived medicinal products (PDMP) in the past several years, particularly in Europe. These diseases include immune deficiencies, immune-mediated peripheral neuropathies, hereditary angioedema, alpha 1-antitrypsin deficiency, hemophilia and other bleeding disorders. In many cases, PDMPs are the only treatment option for these rare and serious diseases. Without these treatments, many patients might not survive or would have a substantially diminished quality of life.

“Improved diagnostic techniques, better awareness among physicians and greater use in emerging markets are further contributing to the growing clinical need for PDMPs. IGs have been proven to prevent or delay the development of comorbidities, positively affect a range of physician- and patient-reported outcomes, including improved quality of life, and are even cost-saving for certain conditions.

“Focused on addressing the growing clinical need for PDMPs, the growth in plasma collection over the past 10 years has mainly come from the private sector and its efficient plasmapheresis programs.”⁵

Advances Overview:

– The Plasma Protein Therapeutics Association (PPTA), representing more than 1,000 plasma collection centers in North America and Europe, produces approximately 80 percent of U.S. plasma protein therapies and 60 percent of those manufactured in Europe

– Improved diagnostic techniques, greater physician awareness and broader emerging market use are all contributing to the growing clinical need for plasma-derived medicinal products (PDMPs)

– IG therapy has been shown to prevent or delay comorbidities, improve physician- and patient-reported outcomes including quality of life and is cost-saving for certain conditions

– Plasma collection growth over the past decade has been driven primarily by the private sector’s plasmapheresis programs

Frequently Asked Questions

What is immune globulin (IG) therapy?

Immune globulin therapy is a medicine derived from pooled donated human blood plasma. It contains concentrated antibodies that help protect the body against disease. IG is administered either intravenously (IVIG) or subcutaneously (SCIG) to treat a range of immune deficiency and autoimmune conditions. For many patients with rare diseases, it is the only available treatment option.

What conditions are treated with IVIG or SCIG?

IG therapy is FDA-approved for primary immune deficiencies such as CVID and XLA, as well as certain neurological and hematological conditions. It is also widely prescribed off-label — in accordance with established clinical guidelines — for conditions including CIDP, Guillain-Barré syndrome, Kawasaki disease, autoimmune encephalopathies and PANDAS/PANS. On-label use accounts for approximately 65 percent of U.S. prescriptions.

What is the difference between IVIG and SCIG?

IVIG (intravenous immune globulin) is infused directly into a vein and is typically administered in a clinical setting. It allows for higher-dose delivery, which is necessary for certain neurological conditions. SCIG (subcutaneous immune globulin) is delivered under the skin at lower doses and can often be administered at home, with fewer infusion-related side effects.

Why is demand for immune globulin growing?

IG demand has grown at an average annual rate exceeding 7 percent over the last five years. Drivers include new research documenting IG’s benefit in autoimmune and neurological conditions, improved diagnostics, post-pandemic catch-up demand and increasing rates of secondary humoral immunodeficiency resulting from B cell-depleting drugs used in oncology and rheumatology.

Are there new FDA-approved IVIG products available?

Yes. Two new 10 percent IVIG products received FDA marketing approval recently: Yimmugo, manufactured by Grifols’ Biotest subsidiary and distributed by Kedrion Biopharma (expected Q1 2025 availability), and ALYGLO, manufactured by GC Biopharma (first shipments initiated July 2024).

What are the main barriers to broader IG therapy access?

The primary barriers are a limited number of FDA-approved indications, high per-patient costs — particularly for high-dose neurological treatments — and inconsistent insurance coverage for off-label use. Supply constraints are also a concern, as large-volume adult dosing can compete with replacement therapy supply for pediatric patients with primary immune deficiency.

Related Content

– Plasma’s Pivotal Role in Cancer Therapy

– The Proven Success of Immune Globulin Therapy to Treat Chronic Inflammatory Demyelinating Polyneuropathy

– SARS-CoV-2 and COVID-19: Plasma Supply and IG Replacement Therapy to Protect Immunodeficient Patients